Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level-Reference-Cited by-同舟云学术

Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level

Published:2006-10-18 Issue:1 Volume:320 Page:323-330
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Katsuno Kenji,Fujimori Yoshikazu,Takemura Yukiko,Hiratochi Masahiro,Itoh Fumiaki,Komatsu Yoshimitsu,Fujikura Hideki,Isaji Masayuki

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference35 articles.

1. Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria

2. Pharmacologic Therapy for Type 2 Diabetes Mellitus

3. Phlorizin: a review

Cited by 246 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of sodium‐glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin‐treated diabetic dogs;Journal of Veterinary Internal Medicine;2024-03-25

2. Medicinal Chemistry Strategies for the Modification of Bioactive Natural Products;Molecules;2024-02-02

3. Synthesis and hydrolysis of aryl fluoroglycosides;Journal of Fluorine Chemistry;2024-01

4. A pharmacokinetic study to correlate the hypoglycemic effect of phlorizin in rats: Identification of metabolites as inhibitors of sodium/glucose cotransporters;Journal of Mass Spectrometry;2023-07-18

5. Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs;Diabetes, Metabolic Syndrome and Obesity;2023-06